ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma

• DOI: 10.3892/or.2021.8234
• Publication Date: 2021-11-26T09:27:06Z
• Authors: Ken Tanaka; Shuya Kandori; Shotaro Sakka; Satoshi Nitta; Kozaburo Tanuma; Masanobu Shiga; Yoshiyuki Nagumo; Hiromitsu Negoro; Takahiro Kojima; Bryan Mathis; Toru Shimazui; Makoto Watanabe; Taka-Aki Sato; Takafumi Miyamoto; Takashi Matsuzaka; Hitoshi Shimano; Hiroyuki Nishiyama
• Keywords: 0301 basic medicine; Fatty Acid Elongases; Apoptosis; Articles; Lipid Metabolism; Kidney Neoplasms; 3. Good health; 03 medical and health sciences; Cell Line, Tumor; Gene Knockdown Techniques; Disease Progression; Humans; CRISPR-Cas Systems; Carcinoma, Renal Cell; Cell Proliferation

Renal cell carcinoma (RCC) is an aggressive genitourinary malignancy which has been associated with a poor prognosis, particularly in patients metastasis, its major subtypes being clear RCC (ccRCC), papillary PCC (pRCC) and chromophobe (chRCC). The presence of intracellular lipid droplets (LDs) considered to be hallmark ccRCC. importance altered metabolism ccRCC widely recognized. elongation very‑long‑chain fatty acid (ELOVL) catalyzes the acids (FAs), modulating composition, required for normal bodily functions. However, involvement elongases remains unclear. In present study, expression ELOVL2 was examined; particular, high levels seven ELOVL isozymes were observed primary tumors. Of note, elevated ccRCC, as well pRCC chRCC. Furthermore, higher level significantly increased incidence prognosis pRCC. CRISPR/Cas9‑mediated knockdown resulted suppression long‑chain polyunsaturated FAs LD production renal cancer cells. Moreover, ablation cellular proliferation via induction apoptosis vitro attenuation tumor growth vivo. On whole, study provides new insight into mechanisms involving metabolism, suggests that may attractive novel target therapy.